Oxidative mutagenesis of doxorubicin-Fe(III) complex

被引:28
作者
Kostoryz, EL [1 ]
Yourtee, DM [1 ]
机构
[1] Univ Missouri, Sch Pharm, Div Pharmacol, Kansas City, MO 64108 USA
关键词
doxorubicin; doxorubicin-Fe(III) complex; Ames strain TA102; ADR-529; oxidative mutagenesis; free radicals;
D O I
10.1016/S1383-5718(00)00158-3
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Doxorubicin has a high affinity for inorganic iron, Fe(III), and has potential to form doxorubicin-Fe(III) complexes in biological systems. Indirect involvement of iron has been substantiated in the oxidative mutagenicity of doxorubicin. In this study, however, direct involvement of Fe(III) was evaluated in mutagenicity studies with the doxorubicin-Fe(III) complex. The Salmonella mutagenicity assay with strain TA102 was used with a pre-incubation step. The highest mutagenicity of doxorubicin-Fe(III) complex was observed at the dose of 2.5 nmol/plate of the complex. The S9-mix decreased this highest mutagenicity but increased the number of revertants at a higher dose of 10 nmol/plate of the complex. On the other hand, the mutagenicity of the doxorubiciu-Fe(III) complex at the doses of 0.25, 0.5, 1 and 2 nmol/plate was enhanced about twice by the. addition of glutathione plus H2O2. This enhanced mutagenicity as well as of the complex itself, the complex plus glutathione, and the complex plus H2O2 were reduced by the addition of ADR-529, an Fe(III) chelator, and potassium iodide, a hydroxyl radical scavenger. These results indicate that doxorubicin-Fe(III) complex exert the mutagenicity through oxidative DNA damage and that Fe(III) is a required element in the mutagenesis of doxorubicin. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:131 / 139
页数:9
相关论文
共 29 条
[1]  
ALDERTON P, 1990, CANCER RES, V50, P5136
[2]   NADPH CYTOCHROME-P-450 REDUCTASE ACTIVATION OF QUINONE ANTI-CANCER AGENTS TO FREE-RADICALS [J].
BACHUR, NR ;
GORDON, SL ;
GEE, MV ;
KON, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (02) :954-957
[3]  
BENEDICT WF, 1977, CANCER RES, V37, P2209
[4]   IRON(III) ADRIAMYCIN AND IRON(III) DAUNORUBICIN COMPLEXES - PHYSICOCHEMICAL CHARACTERISTICS, INTERACTION WITH DNA, AND ANTITUMOR-ACTIVITY [J].
BERALDO, H ;
GARNIERSUILLEROT, A ;
TOSI, L ;
LAVELLE, F .
BIOCHEMISTRY, 1985, 24 (02) :284-289
[5]   ON PHYSICO-CHEMICAL INTERACTIONS BETWEEN DAUNOMYCIN AND NUCLEIC ACIDS [J].
CALENDI, E ;
DIMARCO, A ;
REGGIANI, M ;
SCARPINATO, B ;
VALENTINI, L .
BIOCHIMICA ET BIOPHYSICA ACTA, 1965, 103 (01) :25-+
[6]   GENETIC AND PHYSIOLOGICAL MODULATION OF ANTHRACYCLINE-INDUCED MUTAGENESIS IN SALMONELLA-TYPHIMURIUM [J].
CEBULA, TA .
ENVIRONMENTAL MUTAGENESIS, 1986, 8 (05) :675-692
[7]  
Chlopkiewicz B, 1991, Acta Pol Pharm, V48, P33
[8]   MODULATION OF THE MUTAGENIC RESPONSE IN PROKARYOTES [J].
DEFLORA, S ;
CAMOIRANO, A ;
DAGOSTINI, F ;
BALANSKY, R .
MUTATION RESEARCH, 1992, 267 (02) :183-192
[9]  
DIETRICH MF, 1987, P AM ASSOC CANC RES, V28, P136
[10]  
Ejchart A, 1996, Acta Pol Pharm, V53, P357